Sapir Alex 4
4 · Fulcrum Therapeutics, Inc. · Filed Jul 8, 2024
Insider Transaction Report
Form 4
Sapir Alex
DirectorSee Remarks
Transactions
- Exercise/Conversion
Stock option - Right to Buy
2024-07-03−150,000→ 2,280,400 totalExercise: $3.27Exp: 2033-05-11→ Common Stock (150,000 underlying) - Exercise/Conversion
Common Stock
2024-07-03$3.27/sh+150,000$490,500→ 193,360 total
Footnotes (2)
- [F1]This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
- [F2]This option was granted on May 12, 2023 and vested 25% on the first anniversary of the vesting commencement date of May 12, 2023. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.